本文選題：帕金森病　切入點：非運動癥狀　出處：《山西醫(yī)科大學》2017年碩士論文　論文類型：學位論文

【摘要】：目的:探討鹽酸普拉克索緩釋片對于治療帕金森病非運動癥狀的臨床療效。方法:收集2015年9月至2016年7月期間在山西醫(yī)科大學第二醫(yī)院及山西醫(yī)學科學院神經內科首診的101名帕金森病合并非運動癥狀病人的患病資料(運用MDS最新診斷標準)[11],用隨機分配法分為多巴絲肼片組與普拉克索緩釋片組,通過4周的藥物滴定期和12周的藥物維持期,并分別于2、4、6、8、10、14、16周進行隨訪觀察,運用漢密爾頓焦慮及抑郁量表、帕金森病睡眠量表及認知功能等量表進行觀察評分,同時記錄不良反應,觀察單用多巴絲肼片組與多巴絲肼聯合普拉克索緩釋片組在治療非運動癥狀方面的療效。結果:通過治療觀察,聯合運用普拉克索緩釋片組的患者在睡眠障礙,焦慮及抑郁等情緒障礙的治療效果較單用多巴絲肼片組顯著,差別存在統(tǒng)計學意義(P0.05),但在認知功能障礙、感覺異常和自主功能紊亂等方面,兩組之間差別不存在統(tǒng)計學意義(P0.05)。結論:(1)普拉克索緩釋片作為新型多巴胺受體激動劑,對于治療帕金森病非運動癥狀,具有較好的療效,明顯改善患者焦慮、抑郁狀態(tài)及睡眠障礙;(2)普拉克索緩釋片對于治療帕金森病運動癥狀同樣具有較好的療效;(3)針對帕金森病患者的治療方案,藥物擁有較好的安全性,可以長期使用。
[Abstract]:Objective: to investigate the clinical efficacy of Praxol hydrochloride sustained-release tablets in the treatment of non-motor symptoms of Parkinson's disease. Methods: from September 2015 to July 2016, we collected nerves from the second Hospital of Shanxi Medical University and the Shanxi Academy of Medical Sciences. The clinical data of 101 patients with Parkinson's disease and non-motor symptoms (using the latest diagnostic criteria of MDS) were randomly divided into two groups: dobutazide group and Praxol sustained-release tablet group. The patients were followed up for 4 weeks and 12 weeks, and followed up for 16 weeks, respectively. Hamilton anxiety and depression scale, Parkinson's disease sleep scale and cognitive function scale were used to observe and score. At the same time, adverse reactions were recorded to observe the efficacy of dobutazid alone and combined with praxol sustained-release tablets in the treatment of non-motor symptoms. The results of treatment of sleep disorder, anxiety and depression in patients with sustained-release tablets combined with Praxol were significantly higher than those in the group treated with dobutazide alone. The difference was statistically significant (P 0.05), but in cognitive dysfunction, there was no significant difference between the two groups in the treatment of sleep disorder, anxiety and depression. There is no significant difference between the two groups in terms of sensory abnormality and autonomic dysfunction. Conclusion: as a new dopamine receptor agonist, Platesol sustained-release tablet has a good effect on the treatment of Parkinson's disease with non-motor symptoms. Paxol sustained-release tablets were also effective in the treatment of motor symptoms of Parkinson's disease. It can be used for a long time.
【學位授予單位】：山西醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R742.5

【參考文獻】

相關期刊論文 前7條

1 蔣雨平;;普拉克索緩釋片:帕金森病優(yōu)化治療的新選擇[J];中國臨床神經科學;2015年04期

2 張媛;郭紀鋒;唐北沙;;帕金森病非運動癥狀評定量表的研究進展[J];中華神經科雜志;2014年09期

3 ;中國帕金森病治療指南(第三版)[J];藥學與臨床研究;2014年04期

4 張克忠;袁永勝;宋春杰;張廉;;鹽酸普拉克索改善帕金森病非運動癥狀療效觀察[J];中國實用神經疾病雜志;2012年14期

5 陳生弟;陳偉;;帕金森病非運動癥狀的識別與處理:從忽視到重視[J];中華神經科雜志;2012年06期

6 王心寧;劉桂冬;肖勤;陳生弟;;多巴胺受體激動劑普拉克索治療帕金森病非運動癥狀的療效觀察[J];臨床神經病學雜志;2010年04期

7 葛許華;于春雨;孔德蓮;秦敬翠;周聯生;;普拉克索添加治療帕金森病的臨床研究[J];浙江臨床醫(yī)學;2011年10期

，

本文編號：1604718